Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA)

Study-related travel may be provided at no cost to many study participants and their study partner including flights, ground transportation, lodging, and meals for both the patient and caregiver. Travel arrangements and reimbursements may vary from study to study.

Research trials will provide many patients access to an investigational medication that might slow the progression of Multiple System Atrophy (MSA).

Benefits of participating in clinical trials at no cost to you or your family may include:

  • Lab Work
  • MRI Scans
  • Neurological Exams
  • More Access to Physicians Investigational Medications (Placebo Controlled)
  • Lodging and Meals
  • Travel (Within US for caregiver & patient)

Investigational Treatment for Multiple System Atrophy (MSA)

CenExel RMCR is conducting clinical studies that will provide many patients with a new investigational medication. The study seeks to determine if the investigational treatment will safely slow the progression of MSA.


Multiple system atrophy is a rare disease that affects the nervous system and impacts an individual’s motor function, balance and coordination, blood pressure, heart rate, sexual function, digestion, and elimination.

If you have been diagnosed with multiple system atrophy, you may be experiencing the difficulties outlined above. Daily activities of self-care may be more challenging for you and your loved ones. Symptoms may cause you to feel as though you are losing your independence.


Multiple Systems Atrophy (MSA) is commonly misdiagnosed especially early on in the course of the disease. It usually presents with Parkinsonism (MSA-P) or with incoordination of the limbs and gait (MSA-C). In North America, Parkinsonism is the more common presentation. Although often indistinguishable from Parkinson’s disease early on in the disease, patients with MSA often have more symmetric features of Parkinsonism and may have less tremor compared to patients with Parkinson’s disease. The progression of Parkinsonism is usually more rapid in patients with MSA-P than with patients with Parkinson’s disease. Many patients with MSA-C fail to respond to levodopa therapy or may respond poorly. Of those patients who initially respond to levodopa, most tend to gradually lose their levodopa response over a few years.

Patients with MSA-C have to be distinguished from other causes of incoordination, especially other neurodegenerative diseases affecting the cerebellum such as Spinocerebellar Ataxia.


Parkinsonism in patients with MSA is usually treated with standard antiparkinson’ s medications such as levodopa. For patients that develop involuntary movements (dyskinesia) associated with levodopa, amantadine may be used to reduce these abnormal involuntary movements. In addition, some patients who fail to respond to levodopa or who respond poorly may have additional benefit for bradykinesia (slowness of movement) with amantadine therapy. Amantadine may also be used for incoordination associated with MSA-C though it is likely that less than 25% of patients have a clinically significant improvement for incoordination. Botulinum toxin (Botox) injections may be used for abnormal posturing (dystonia) or muscle spasms. Blood pressure drops causing lightheadedness or fainting is often treated with lifestyle measures (increased fluids and salt, compression stockings, abdominal binder) and medications to increase blood pressure (e.g. midodrine, fludrocortisone, droxidopa, and pyridostigmine). Bladder dysfunction may be treated with standard medications to reduce urinary urgency (e.g. trospium, tolterodine, etc.), but when bladder control becomes increasingly poor, use of a catheter or diaper may be indicated. Constipation is often problematic for MSA patients and taking extra fluids and fiber may be helpful in addition to a combination of laxatives (e.g. MiraLAX, Senokot, etc.).

Most patients with MSA can benefit from physical therapy, predominantly focusing on gait and balance to prevent falls as well as a stretching and home exercise program to maintain fitness and prevent deconditioning and the development of contractures (reduced range of motion of joints). As the disease progresses, use of a walking aid such as a cane or walker is typically needed. Manual dexterity may be affected both by Parkinsonism and incoordination so occupational therapy intervention to help with a use of adaptive devices may help to maintain independence for activities of daily living. Speech and swallowing are often affected and may result in difficulties with eating and drinking. Speech therapy focusing on loudness of speech may be helpful for some patients with softness usually associated with MSA-P. As MSA progresses, patients may develop choking or coughing, more commonly when drinking than when eating. Swallowing evaluation, with the help of a speech therapist, is often helpful to guide instruction on compensatory techniques to reduce the risk of pneumonia caused by food or liquid entering the lungs. When the risk of pneumonia becomes high, some patients benefit from dietary alterations including thickening of liquids and change in food textures. Some patients elect to undergo feeding tube placement to enable maintenance of nutrition.


There is currently extensive research ongoing to better understand the cause and progression of MSA.

Medical professionals are evaluating an investigational medication designed to suppress an enzyme called myeloperoxidase (MPO), believed to cause inflammation and damage to neurons in the brains of patients with multiple system atrophy. The main purpose of the study is to see if it helps slow disease progression. The investigational medication tablets are taken twice daily.

Patients who are already taking stable doses of medications used to treat MSA symptoms may be able to continue their current medications while participating in the study. After determining eligibility, study participation lasts for about 11 months and requires participation from a patient caregiver who will need to attend seven study visits spread out over that time with the patient.

Do you or a loved one have MSA?

Please fill out the survey to help us determine if you, or your loved one, may qualify for an investigational study aiming to potentially slow disease progression.


Do you or a loved one have MSA?

Please fill out the below survey to help us determine if you, or your loved one, may qualify for an investigational study aiming to potentially slow disease progression.

Has the patient been diagnosed with Multiple System Atrophy (MSA)?


When did you first notice MSA symptoms?


Can the patient walk 10 steps independently or with a little help (using a cane, walker, or holding onto someone with one hand)?


Does the patient live in a nursing home?


What is the patient's age?

Your Name

First Name
Last Name

Relationship to Patient*

If you are submitting this form on behalf of someone else, you must have that person's consent unless you have a medical power of attorney.



Email is generally not encrypted. If you do not wish to accept the risks associated with communicating your Personal Information by email, please provide only your phone number.


Space in this study is limited.
To be considered, please fill out the form or call 720-776-0092.


No cost studies are currently available for qualified participants.


No health insurance required


Compensation for time and travel TBD



Male / Female



701 E Hampden Ave, Ste 510
Englewood, CO 80113

State-of-the-Art Facilities

CenExel RMCR is Colorado's premier clinical research organization. For over 15 years, we’ve helped improve the quality of life for everyone by researching new medications and treatments. Our state-of-the-art facility is held to the highest standards of cleanliness and quality.

Board-Certified Physician

Your safety is our greatest concern. Every study at CenExel RMCR is overseen by expert medical staff and one of the most well-respected, board-certified physicians in the clinical research industry with 25+ years of experience.

FDA-Approved Procedures

Rest assured, you are not signing up for treatment with “experimental” methods. RMCR only uses FDA approved methods as if you were at any other hospital or clinic. Our research is focused on the medication associated with those methods.

Frequently asked questions

What is a CenExel Center of Excellence?

CenExel Centers of Excellence provide unparalleled medical and scientific support in the design and execution of clinical trials. Their attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. They have conducted thousands of studies, the variety and complexity of which have resulted in a great depth of experience and insight for the principal investigators and research staff in each facility. CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that clients achieve their clinical research goals.

How do clinical trials work?

The study procedures and process will vary depending on the type of clinical trial you participate in. Before you begin a study, the process and all procedures for that study will be explained to you. Throughout the study, the Study Coordinator and the Principal Investigator will assist you and can answer any questions you have. They will check your health at the beginning of the trial, give you specific instructions for participating in the trial, monitor you carefully during the trial, and stay in touch with you after the study.

Some clinical trials involve more tests and doctor visits than you would normally have for your illness or condition. Your participation will be most successful if you carefully follow all instructions you are given and stay in contact with the research staff.

How safe are clinical studies?

There are many safeguards in place that all companies must follow when conducting clinical trials.

The Food and Drug Administration (FDA) is the regulatory agency that oversees all clinical research conducted in the United States. It is their responsible to protect the rights and as much as possible, the welfare of subjects participating in clinical trials. They ensure that data collected from clinical trials is of the highest quality and they are the agency that determines whether a new treatment should be sold in the US. Several organizations and individuals are governed by FDA regulations including clinical investigators, sponsors (the companies developing the treatments), Contract Research Organizations (companies that help conduct the studies), and Institutional Review Boards (groups that are responsible for ensuring the safety and welfare of study participants).

Good Clinical Practice (GCP) guidelines are another safeguard implemented to protect the safety of subjects. These guidelines encompass federal regulations and industry-accepted standards that govern clinical trials on humans. These regulations and standards apply to the conduct of the studies, record keeping, informed consent of subjects, collection of scientific data, and submission of information needed for the FDA to determine whether a new treatment should or should not be sold in the US. All companies must follow these guidelines when conducting clinical research.

An Institutional Review Board (IRB) is a committee that is formally tasked by an institution to review, approve, and monitor research involving human subjects. IRBs ensure that the risks to subjects are minimized; that subjects are adequately informed about the trial and the implications it will have on their treatment; that study protocols are modified, when necessary, to ensure safety; that risks are reasonable in relation to the anticipated benefits and the importance of the knowledge to be gained; that subject selection is equitable and that no classes of patients are discriminated against; that informed consent is obtained; that there is a provision for safety monitoring in the research plan; and that here are adequate provisions for the privacy and confidentiality for subjects and the data collected.

Translate »